Haplo-cord Transplantation: Overcoming the Limitations of Umbilical Cord Blood (UCB) Transplantation (UCBT)

Chapter
Part of the Stem Cell Biology and Regenerative Medicine book series (STEMCELL)

Abstract

The low cell dose in umbilical cord blood (UCB) transplantation (UCBT) can be a limiting factor for engraftment, and is associated with a higher incidence of infection. The infusion of UCB cells with CD34-selected donor stem cells from an adult typically results in rapid hematopoietic recovery from adult donor cells that are over time replaced by definitive hemato- and lymphopoiesis from the cord blood graft. Initially pioneered by Fernandez and colleagues in Spain, this technology is now being implemented in several centers. Clinical trial data from Europe and the USA will be presented in this chapter. Combination UCB and haploidentical transplants are an exciting new strategy to improve transplant outcomes.

Keywords

Cord blood Transplantation Haploidentical CD34 selected Engraftment 

References

  1. 1.
    Fernandez MN, Regidor C, Cabrera R, et al. Unrelated umbilical cord blood transplants in adults: early recovery of neutrophils by supportive co-transplantation of a low number of highly purified peripheral blood CD34 + cells from an HLA-haploidentical donor. Exp Hematol. 2003;31:535–44.PubMedCrossRefGoogle Scholar
  2. 2.
    Fernandez MN, Bautista G, Regidor C, et al. CBT: use of haplo-identical and unrelated donors to act as a myeloid bridge [abstract]. 10th International Cord Blood Symposium 2012;20.Google Scholar
  3. 3.
    Bautista G, Cabrera JR, Regidor C, et al. Cord blood transplants supported by co-infusion of mobilized hematopoietic stem cells from a third-party donor. Bone Marrow Transplant. 2009;43:365–73.PubMedCrossRefGoogle Scholar
  4. 4.
    Kwon M, Balsasobre P, Anguita J, et al. Expanding the usefulness of dual transplantation: cord blood combined with third party HLA-mismatched donor and reduced intensity conditioning [abstract]. Blood. 2011;118:e letter December 2011.Google Scholar
  5. 5.
    Gormley NJ, Wilder J, Khuu H, et al. Co-infusion of allogeneic cord blood with haploidentical CD34 + cells improved transplant outcome for patients with severe aplastic anemia undergoing cord blood transplantation. Blood (ASH Annual Meeting Abstracts). 2011;118:654.Google Scholar
  6. 6.
    Lindemans CA, Kuball JHE, te Boome LCJ, et al. Coinfusion of haploidentical donor stem cells with unrelated cord blood [abstract]. 10th International Cord Blood Symposium 2012;5.Google Scholar
  7. 7.
    Liu H, Rich ES, Godley L, et al. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood. 2011;118:6438–45.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Ponce DM, Dahi PB, Devlin S, et al. Double-unit cord blood (CB) transplantation combined with haplo-identical CD34 + cell-selected PBSC results in 100 % CB engraftment with enhanced myeloid recovery. Blood. 2013;122:298.CrossRefGoogle Scholar
  9. 9.
    van Besien KD, Devine S Wickrema A, et al. Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies. Bone Marrow Transplant. 2003;32:9–13.PubMedCrossRefGoogle Scholar
  10. 10.
    Yoshihara S, Taniguchi K, Ogawa H, Saji H. The role of HLA antibodies in allogeneic SCT: is the ‘type-and-screen’ strategy necessary not only for blood type but also for HLA? Bone Marrow Transplant. 2012;47:1499–506.PubMedCrossRefGoogle Scholar
  11. 11.
    Ruggeri A, Rocha V, Masson E, et al. Impact of donor-specific anti-HLA antibodies on graft failure and survival after reduced intensity conditioning-unrelated cord blood transplantation: a Eurocord, Societe Francophone d’Histocompatibilite et d’Immunogenetique (SFHI) and Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC) analysis. Haematologica. 2013;98:1154–60.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Cutler C, Kim HT, Sun L, et al. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood. 2011;118:6691–7.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Gergis U, Mayer S, Gordon B, et al. An approach to reducing the burden of donor specific HLA antibodies prior to allogeneic stem cell transplantation. Bone Marrow Transplant. 2014(e-pub ahead of publication).Google Scholar
  14. 14.
    Barker JN, Byam C, Scaradavou A. How I treat: the selection and acquisition of unrelated cord blood grafts. Blood. 2011;117:2332–9.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Cairo MS, Wagner EL, Fraser J, et al. Characterization of banked umbilical cord blood hematopoietic progenitor cells and lymphocyte subsets and correlation with ethnicity, birth weight, sex, and type of delivery: a cord blood transplantation (COBLT) study report. Transfusion. 2005;45:856–66.PubMedCrossRefGoogle Scholar
  16. 16.
    Eapen M, Klein JP, Ruggeri A, et al. Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood. 2014;123:133–40.PubMedCrossRefGoogle Scholar
  17. 17.
    Landgren O, Gilbert ES, Rizzo JD, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood. 2009;113:4992–5001.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Martino R, Bretagne S, Einsele H, et al. Early detection of Toxoplasma infection by molecular monitoring of Toxoplasma gondii in peripheral blood samples after allogeneic stem cell transplantation. Clin Infect Dis. 2005;40:67–78.PubMedCrossRefGoogle Scholar
  19. 19.
    Kline J, Pollyea D, Larson RA, et al. Ganciclovir and high-dose valacyclovir prevent cytomegalovirus reactivation in patients receiving allogeneic stem cell transplants with Campath-1H based conditioning regimens. Biol Blood Marrow Transplant. 2005;11 Suppl 1:94.CrossRefGoogle Scholar
  20. 20.
    van Besien K. Haplo cord transplantation: rapid neutrophil and platelet recovery and improved long-term survival compared to double umbilical cord blood (UCB) transplantation, a case-cohort analysis [abstract]. ASCO Proceedings 2014.Google Scholar
  21. 21.
    Kwon M, Martinez-Laperche C, Balsalobre P, et al. Early peripheral blood and T-cell chimerism dynamics after umbilical cord blood transplantation supported with haploidentical cells. Bone Marrow Transplant. 2013;49:212–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Kwon M, Kuball J, Ellerbroek P. Single cord blood transplantation combined with an HLA mismatched third party donor for high-risk hematological patients with HIV infection [abstract]. Blood. 2013;122:3401.Google Scholar
  23. 23.
    Tian X, Wilder J, Gormley N, et al. NK cell KIR ligand mismatches influence engraftment following combined haploidentical and umbilical cord blood (UCB) transplantation in patients with severe aplastic anemia (SAA). Blood. 2013;122:2038.Google Scholar
  24. 24.
    Van BK, Liu H, Jain N, Stock W, Artz A. Umbilical cord blood transplantation supported by third-party donor cells: rationale, results, and applications. Biol Blood Marrow Transplant. 2013;19:682–91.CrossRefGoogle Scholar
  25. 25.
    van Besien K, Jain N, Schouten V, et al. Immune-reconstitution after combined haploidentical and umbilical cord blood transplantation [abstract]. ASCO Meeting Abstracts 2012;6535.Google Scholar
  26. 26.
    Martin-Donaire T, Rico M, Bautista G, et al. Immune reconstitution after cord blood transplants supported by coinfusion of mobilized hematopoietic stem cells from a third party donor. Bone Marrow Transplant. 2009;44:213–25.PubMedCrossRefGoogle Scholar
  27. 27.
    Kwon M, Balsalobre P, Serrano D, et al. Single cord blood combined with HLA-mismatched third-party donor cells: comparable results to matched-unrelated donor transplantation in high-risk patients with hematologic disorders. Biol Blood Marrow Transplant. 2012;19:143–9 (e-pub).PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.Weill Cornell Medical CollegeNew YorkUSA

Personalised recommendations